Serveur d'exploration Stress et Covid

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.

Identifieur interne : 000A32 ( PubMed/Corpus ); précédent : 000A31; suivant : 000A33

Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.

Auteurs : A. Amberger ; M. Hala ; M. Saurwein-Teissl ; B. Metzler ; B. Grubeck-Loebenstein ; Q. Xu ; G. Wick

Source :

RBID : pubmed:10203577

English descriptors

Abstract

Studies from our laboratory have shown that the earliest stages of atherosclerosis may be mediated by an autoimmune reaction against heat shock protein 60 (Hsp60). The interactions of Hsp60-specific T cells with arterial endothelial cells (EC) require expression of both Hsp60 and certain adhesion molecules shown to be induced simultaneously in EC by mechanical and other types of stress. Recently, it was shown that suppression of T cell-mediated immune responses by cyclosporin A (CyA) enhanced atherosclerotic lesion formation in mice. In contrast, aspirin was found to lower the risk of myocardial infarction in men. These conflicting observations may be due to different effects of anti-inflammatory agents on adhesion molecule and Hsp expression in EC, respectively.

PubMed: 10203577

Links to Exploration step

pubmed:10203577

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.</title>
<author>
<name sortKey="Amberger, A" sort="Amberger, A" uniqKey="Amberger A" first="A" last="Amberger">A. Amberger</name>
<affiliation>
<nlm:affiliation>Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hala, M" sort="Hala, M" uniqKey="Hala M" first="M" last="Hala">M. Hala</name>
</author>
<author>
<name sortKey="Saurwein Teissl, M" sort="Saurwein Teissl, M" uniqKey="Saurwein Teissl M" first="M" last="Saurwein-Teissl">M. Saurwein-Teissl</name>
</author>
<author>
<name sortKey="Metzler, B" sort="Metzler, B" uniqKey="Metzler B" first="B" last="Metzler">B. Metzler</name>
</author>
<author>
<name sortKey="Grubeck Loebenstein, B" sort="Grubeck Loebenstein, B" uniqKey="Grubeck Loebenstein B" first="B" last="Grubeck-Loebenstein">B. Grubeck-Loebenstein</name>
</author>
<author>
<name sortKey="Xu, Q" sort="Xu, Q" uniqKey="Xu Q" first="Q" last="Xu">Q. Xu</name>
</author>
<author>
<name sortKey="Wick, G" sort="Wick, G" uniqKey="Wick G" first="G" last="Wick">G. Wick</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10203577</idno>
<idno type="pmid">10203577</idno>
<idno type="wicri:Area/PubMed/Corpus">000A32</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A32</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.</title>
<author>
<name sortKey="Amberger, A" sort="Amberger, A" uniqKey="Amberger A" first="A" last="Amberger">A. Amberger</name>
<affiliation>
<nlm:affiliation>Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Hala, M" sort="Hala, M" uniqKey="Hala M" first="M" last="Hala">M. Hala</name>
</author>
<author>
<name sortKey="Saurwein Teissl, M" sort="Saurwein Teissl, M" uniqKey="Saurwein Teissl M" first="M" last="Saurwein-Teissl">M. Saurwein-Teissl</name>
</author>
<author>
<name sortKey="Metzler, B" sort="Metzler, B" uniqKey="Metzler B" first="B" last="Metzler">B. Metzler</name>
</author>
<author>
<name sortKey="Grubeck Loebenstein, B" sort="Grubeck Loebenstein, B" uniqKey="Grubeck Loebenstein B" first="B" last="Grubeck-Loebenstein">B. Grubeck-Loebenstein</name>
</author>
<author>
<name sortKey="Xu, Q" sort="Xu, Q" uniqKey="Xu Q" first="Q" last="Xu">Q. Xu</name>
</author>
<author>
<name sortKey="Wick, G" sort="Wick, G" uniqKey="Wick G" first="G" last="Wick">G. Wick</name>
</author>
</analytic>
<series>
<title level="j">Molecular medicine (Cambridge, Mass.)</title>
<idno type="ISSN">1076-1551</idno>
<imprint>
<date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Anti-Inflammatory Agents, Non-Steroidal (pharmacology)</term>
<term>Aspirin (pharmacology)</term>
<term>Cell Division (drug effects)</term>
<term>Cells, Cultured (drug effects)</term>
<term>Cells, Cultured (metabolism)</term>
<term>Chaperonin 60 (drug effects)</term>
<term>Chaperonin 60 (metabolism)</term>
<term>Chemokine CCL2 (metabolism)</term>
<term>Cyclosporine (pharmacology)</term>
<term>E-Selectin (drug effects)</term>
<term>E-Selectin (metabolism)</term>
<term>Endothelium, Vascular (cytology)</term>
<term>Endothelium, Vascular (drug effects)</term>
<term>Endothelium, Vascular (metabolism)</term>
<term>Female</term>
<term>HSP70 Heat-Shock Proteins (drug effects)</term>
<term>HSP70 Heat-Shock Proteins (metabolism)</term>
<term>Heat-Shock Proteins (drug effects)</term>
<term>Heat-Shock Proteins (metabolism)</term>
<term>Humans</term>
<term>Immunosuppressive Agents (pharmacology)</term>
<term>Indomethacin (pharmacology)</term>
<term>Intercellular Adhesion Molecule-1 (drug effects)</term>
<term>Intercellular Adhesion Molecule-1 (metabolism)</term>
<term>Lymphocytes (drug effects)</term>
<term>Lymphocytes (metabolism)</term>
<term>Male</term>
<term>NF-kappa B (drug effects)</term>
<term>NF-kappa B (genetics)</term>
<term>NF-kappa B (metabolism)</term>
<term>Transcription Factors (drug effects)</term>
<term>Transcription Factors (genetics)</term>
<term>Transcription Factors (metabolism)</term>
<term>Vascular Cell Adhesion Molecule-1 (drug effects)</term>
<term>Vascular Cell Adhesion Molecule-1 (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en">
<term>Chaperonin 60</term>
<term>E-Selectin</term>
<term>HSP70 Heat-Shock Proteins</term>
<term>Heat-Shock Proteins</term>
<term>Intercellular Adhesion Molecule-1</term>
<term>NF-kappa B</term>
<term>Transcription Factors</term>
<term>Vascular Cell Adhesion Molecule-1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>NF-kappa B</term>
<term>Transcription Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Chaperonin 60</term>
<term>Chemokine CCL2</term>
<term>E-Selectin</term>
<term>HSP70 Heat-Shock Proteins</term>
<term>Heat-Shock Proteins</term>
<term>Intercellular Adhesion Molecule-1</term>
<term>NF-kappa B</term>
<term>Transcription Factors</term>
<term>Vascular Cell Adhesion Molecule-1</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Anti-Inflammatory Agents, Non-Steroidal</term>
<term>Aspirin</term>
<term>Cyclosporine</term>
<term>Immunosuppressive Agents</term>
<term>Indomethacin</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Endothelium, Vascular</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Cell Division</term>
<term>Cells, Cultured</term>
<term>Endothelium, Vascular</term>
<term>Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Cells, Cultured</term>
<term>Endothelium, Vascular</term>
<term>Lymphocytes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Studies from our laboratory have shown that the earliest stages of atherosclerosis may be mediated by an autoimmune reaction against heat shock protein 60 (Hsp60). The interactions of Hsp60-specific T cells with arterial endothelial cells (EC) require expression of both Hsp60 and certain adhesion molecules shown to be induced simultaneously in EC by mechanical and other types of stress. Recently, it was shown that suppression of T cell-mediated immune responses by cyclosporin A (CyA) enhanced atherosclerotic lesion formation in mice. In contrast, aspirin was found to lower the risk of myocardial infarction in men. These conflicting observations may be due to different effects of anti-inflammatory agents on adhesion molecule and Hsp expression in EC, respectively.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">10203577</PMID>
<DateCompleted>
<Year>1999</Year>
<Month>06</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">1076-1551</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>5</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1999</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Molecular medicine (Cambridge, Mass.)</Title>
<ISOAbbreviation>Mol. Med.</ISOAbbreviation>
</Journal>
<ArticleTitle>Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.</ArticleTitle>
<Pagination>
<MedlinePgn>117-28</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies from our laboratory have shown that the earliest stages of atherosclerosis may be mediated by an autoimmune reaction against heat shock protein 60 (Hsp60). The interactions of Hsp60-specific T cells with arterial endothelial cells (EC) require expression of both Hsp60 and certain adhesion molecules shown to be induced simultaneously in EC by mechanical and other types of stress. Recently, it was shown that suppression of T cell-mediated immune responses by cyclosporin A (CyA) enhanced atherosclerotic lesion formation in mice. In contrast, aspirin was found to lower the risk of myocardial infarction in men. These conflicting observations may be due to different effects of anti-inflammatory agents on adhesion molecule and Hsp expression in EC, respectively.</AbstractText>
<AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">In the present study, we analyzed the effects of CyA, aspirin, and indomethacin on T cell proliferation using a proliferation assay. To explore the expression of adhesion molecules, monocyte chemoattractant protein-1 (MCP-1), and Hsp60 in human umbilical vein endothelial cells (HUVECs), Northern blot analyses were used. To examine the activation status of the transcription factors nuclear factor kappaB (NF-kappaB) and heat shock factor-1 (HSF-1), electrophoretic mobility shift assays were performed.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">With the exception of indomethacin, the used immunosuppressive and anti-inflammatory agents significantly inhibited T cell proliferation in response to influenza virus antigen in a dose-dependent manner. Interestingly, CyA and indomethacin did not suppress tumor necrosis factor-alpha (TNF-alpha)-induced adhesion molecule expression on HUVECs, whereas aspirin had an inhibitory effect. These observations correlated with the modulation of NF-kappaB activity in EC. All agents tested induced expression of Hsp60 6 hr after application. In addition, aspirin and indomethacin, but not CyA, induced Hsp70 expression in HUVECs that correlated with induction of HSF-1 activity.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results show that the tested agents (except indomethacin) are inhibitors of the T cell-mediated immune response, as expected, that aspirin is an effective suppressor of adhesion molecule expression, and that all three agents can induce Hsp60 in HUVECs. These data provide the molecular basis for the notion that (1) part of the anti-atherogenic effect of aspirin may be due to the prevention of the adhesion of sensitized T cells to stressed EC; (2) that part of the atherosclerosis-promoting effect of CyA may be due to its potential as an inducer of Hsp60 expression and its inability to down-regulate adhesion molecule expression on EC; and (3) that down-regulation of MCP-1 expression by aspirin may result in decreased recruitment of monocytes into the arterial intima beneath stressed EC.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Amberger</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hala</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Saurwein-Teissl</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Metzler</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Grubeck-Loebenstein</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Xu</LastName>
<ForeName>Q</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Wick</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Mol Med</MedlineTA>
<NlmUniqueID>9501023</NlmUniqueID>
<ISSNLinking>1076-1551</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018834">Chaperonin 60</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018932">Chemokine CCL2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019040">E-Selectin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019010">Vascular Cell Adhesion Molecule-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>126547-89-5</RegistryNumber>
<NameOfSubstance UI="D018799">Intercellular Adhesion Molecule-1</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>83HN0GTJ6D</RegistryNumber>
<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>R16CO5Y76E</RegistryNumber>
<NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>XXE1CET956</RegistryNumber>
<NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002455" MajorTopicYN="N">Cell Division</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018834" MajorTopicYN="N">Chaperonin 60</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018932" MajorTopicYN="N">Chemokine CCL2</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019040" MajorTopicYN="N">E-Selectin</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004730" MajorTopicYN="N">Endothelium, Vascular</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018799" MajorTopicYN="N">Intercellular Adhesion Molecule-1</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019010" MajorTopicYN="N">Vascular Cell Adhesion Molecule-1</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>1999</Year>
<Month>4</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>1999</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>1999</Year>
<Month>4</Month>
<Day>16</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">10203577</ArticleId>
<ArticleId IdType="pii">0092</ArticleId>
<ArticleId IdType="pmc">PMC2230414</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Arthritis Rheum. 1984 Apr;27(4):398-403</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6585206</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Stress Chaperones. 1997 Jun;2(2):94-103</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9250400</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anal Biochem. 1987 Apr;162(1):156-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2440339</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 1988 May;81(5):1608-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3130398</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Atherosclerosis. 1988 Aug;72(2-3):135-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3063267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1989 Jul;135(1):169-75</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2505620</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Mol Cell Biol. 1990 Feb;10(2):752-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2405254</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Immunol Immunopathol. 1990 Sep;56(3):344-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2202532</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol Methods. 1991 Jun 3;139(2):271-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1710634</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunobiology. 1990 Nov;181(4-5):345-56</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2151598</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Annu Rev Biochem. 1991;60:321-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1679318</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb. 1992 Feb;12(2):206-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1531930</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1992 Mar 6;255(5049):1243-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1546322</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1992 Apr;140(4):889-96</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1348606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Today. 1992 Apr;13(4):136-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1374612</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Arterioscler Thromb. 1992 Jul;12(7):789-99</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1616904</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Physiol Rev. 1992 Oct;72(4):1063-81</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1438579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1992 Dec;141(6):1427-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1281621</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 1993 Jan 30;341(8840):255-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8093914</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 1993 Apr 29;362(6423):801-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8479518</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1993 Jun;142(6):1906-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8506958</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 1993 Jun;91(6):2693-702</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8514876</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1993 Dec;143(6):1551-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7504883</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 1994 Jan 28;76(2):301-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7507411</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 1994 Aug 12;265(5174):956-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8052854</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Today. 1995 Jan;16(1):27-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7880386</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Circulation. 1995 Apr 1;91(7):1914-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7534663</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>FASEB J. 1995 Jul;9(10):899-909</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7542214</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Invest. 1995 Sep;96(3):1389-94</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7657813</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Atherosclerosis. 1995 Aug;116(2):181-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7575773</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lab Invest. 1996 Jan;74(1):241-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8569188</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunology. 1995 Dec;86(4):506-11</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8567013</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1996 May 15;156(10):3961-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8621937</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1996 Jun 15;156(12):4617-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8648104</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1996 Aug;149(2):359-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8701976</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 1997 Apr 3;336(14):973-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9077376</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6326095</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A32 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000A32 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    StressCovidV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:10203577
   |texte=   Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:10203577" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a StressCovidV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed May 6 16:44:09 2020. Site generation: Sun Mar 28 08:26:57 2021